Rashid K. Sayyid/X
Feb 19, 2025, 17:22
Rashid K. Sayyid: COSMIC-313 final results
Rashid K. Sayyid, Urology Resident in the Department of Surgery at Augusta University, shared a post on X:
“COSMIC-313: Final results.
Ipi + Nivo +/- Cabo in aRCC pts (n=885, f/u: 45 mo):
- PFS benefit: 16.6 vs 11.2 mo (limited to IMDC int risk only: 22.1 vs 11.3 mo; poor risk: 9.5 vs 11.2 mo).
- No OS benefit in overall, int or poor risk groups.
- Triplet combo not well tolerated (only 50% tolerated all 4 cycles of Ipi).
- RNA seq data Tumors w/ M2-like macrophages benefited most from cabo addition to ipi + nivo.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 20, 2025, 11:19
Feb 20, 2025, 11:13
Feb 20, 2025, 11:08
Feb 20, 2025, 11:00
Feb 20, 2025, 10:52
Feb 20, 2025, 10:45